| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | cytidine deaminase activity | 7.85e-10 | 13 | 22 | 4 | GO:0004126 | |
| GeneOntologyMolecularFunction | deaminase activity | 5.01e-08 | 34 | 22 | 4 | GO:0019239 | |
| GeneOntologyMolecularFunction | hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines | 6.36e-08 | 36 | 22 | 4 | GO:0016814 | |
| GeneOntologyMolecularFunction | apolipoprotein binding | 1.31e-06 | 20 | 22 | 3 | GO:0034185 | |
| GeneOntologyMolecularFunction | hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds | 1.81e-05 | 146 | 22 | 4 | GO:0016810 | |
| GeneOntologyMolecularFunction | protein antigen binding | 1.38e-04 | 16 | 22 | 2 | GO:1990405 | |
| GeneOntologyMolecularFunction | zinc ion binding | 3.13e-04 | 891 | 22 | 6 | GO:0008270 | |
| GeneOntologyMolecularFunction | transition metal ion binding | 1.44e-03 | 1189 | 22 | 6 | GO:0046914 | |
| GeneOntologyMolecularFunction | peptidase activity | 5.21e-03 | 654 | 22 | 4 | GO:0008233 | |
| GeneOntologyBiologicalProcess | DNA cytosine deamination | 1.66e-10 | 10 | 21 | 4 | GO:0070383 | |
| GeneOntologyBiologicalProcess | cytidine to uridine editing | 3.91e-10 | 12 | 21 | 4 | GO:0016554 | |
| GeneOntologyBiologicalProcess | cytidine metabolic process | 7.89e-10 | 14 | 21 | 4 | GO:0046087 | |
| GeneOntologyBiologicalProcess | cytidine catabolic process | 7.89e-10 | 14 | 21 | 4 | GO:0006216 | |
| GeneOntologyBiologicalProcess | cytidine deamination | 7.89e-10 | 14 | 21 | 4 | GO:0009972 | |
| GeneOntologyBiologicalProcess | DNA deamination | 7.89e-10 | 14 | 21 | 4 | GO:0045006 | |
| GeneOntologyBiologicalProcess | negative regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1.43e-09 | 16 | 21 | 4 | GO:0045869 | |
| GeneOntologyBiologicalProcess | pyrimidine ribonucleoside metabolic process | 1.43e-09 | 16 | 21 | 4 | GO:0046131 | |
| GeneOntologyBiologicalProcess | pyrimidine ribonucleoside catabolic process | 1.43e-09 | 16 | 21 | 4 | GO:0046133 | |
| GeneOntologyBiologicalProcess | pyrimidine nucleoside catabolic process | 2.41e-09 | 18 | 21 | 4 | GO:0046135 | |
| GeneOntologyBiologicalProcess | regulation of single stranded viral RNA replication via double stranded DNA intermediate | 3.05e-09 | 19 | 21 | 4 | GO:0045091 | |
| GeneOntologyBiologicalProcess | base conversion or substitution editing | 3.05e-09 | 19 | 21 | 4 | GO:0016553 | |
| GeneOntologyBiologicalProcess | single stranded viral RNA replication via double stranded DNA intermediate | 3.81e-09 | 20 | 21 | 4 | GO:0039692 | |
| GeneOntologyBiologicalProcess | ribonucleoside catabolic process | 1.17e-08 | 26 | 21 | 4 | GO:0042454 | |
| GeneOntologyBiologicalProcess | pyrimidine nucleoside metabolic process | 1.37e-08 | 27 | 21 | 4 | GO:0006213 | |
| GeneOntologyBiologicalProcess | DNA modification | 2.45e-08 | 31 | 21 | 4 | GO:0006304 | |
| GeneOntologyBiologicalProcess | viral RNA genome replication | 2.80e-08 | 32 | 21 | 4 | GO:0039694 | |
| GeneOntologyBiologicalProcess | nucleoside catabolic process | 2.80e-08 | 32 | 21 | 4 | GO:0009164 | |
| GeneOntologyBiologicalProcess | nucleobase-containing small molecule catabolic process | 5.13e-08 | 37 | 21 | 4 | GO:0034656 | |
| GeneOntologyBiologicalProcess | glycosyl compound catabolic process | 7.85e-08 | 41 | 21 | 4 | GO:1901658 | |
| GeneOntologyBiologicalProcess | pyrimidine-containing compound catabolic process | 1.26e-07 | 46 | 21 | 4 | GO:0072529 | |
| GeneOntologyBiologicalProcess | ribonucleoside metabolic process | 1.50e-07 | 48 | 21 | 4 | GO:0009119 | |
| GeneOntologyBiologicalProcess | negative regulation of viral genome replication | 2.82e-07 | 56 | 21 | 4 | GO:0045071 | |
| GeneOntologyBiologicalProcess | nucleoside metabolic process | 6.20e-07 | 68 | 21 | 4 | GO:0009116 | |
| GeneOntologyBiologicalProcess | carbohydrate derivative catabolic process | 6.27e-07 | 323 | 21 | 6 | GO:1901136 | |
| GeneOntologyBiologicalProcess | trophoblast giant cell differentiation | 8.72e-07 | 19 | 21 | 3 | GO:0060707 | |
| GeneOntologyBiologicalProcess | regulation of viral genome replication | 2.00e-06 | 91 | 21 | 4 | GO:0045069 | |
| GeneOntologyBiologicalProcess | pyrimidine-containing compound metabolic process | 2.09e-06 | 92 | 21 | 4 | GO:0072527 | |
| GeneOntologyBiologicalProcess | glycosyl compound metabolic process | 2.48e-06 | 96 | 21 | 4 | GO:1901657 | |
| GeneOntologyBiologicalProcess | negative regulation of viral process | 3.29e-06 | 103 | 21 | 4 | GO:0048525 | |
| GeneOntologyBiologicalProcess | cell differentiation involved in embryonic placenta development | 5.33e-06 | 34 | 21 | 3 | GO:0060706 | |
| GeneOntologyBiologicalProcess | positive regulation of fibrinolysis | 9.85e-06 | 5 | 21 | 2 | GO:0051919 | |
| GeneOntologyBiologicalProcess | viral genome replication | 1.02e-05 | 137 | 21 | 4 | GO:0019079 | |
| GeneOntologyBiologicalProcess | transposable element silencing | 1.34e-05 | 46 | 21 | 3 | GO:0010526 | |
| GeneOntologyBiologicalProcess | clearance of foreign intracellular DNA | 1.48e-05 | 6 | 21 | 2 | GO:0044355 | |
| GeneOntologyBiologicalProcess | clearance of foreign intracellular nucleic acids | 1.48e-05 | 6 | 21 | 2 | GO:0099046 | |
| GeneOntologyBiologicalProcess | retrotransposition | 1.53e-05 | 48 | 21 | 3 | GO:0032197 | |
| GeneOntologyBiologicalProcess | regulation of viral life cycle | 1.70e-05 | 156 | 21 | 4 | GO:1903900 | |
| GeneOntologyBiologicalProcess | transposition | 1.73e-05 | 50 | 21 | 3 | GO:0032196 | |
| GeneOntologyBiologicalProcess | trans-synaptic signaling by BDNF, modulating synaptic transmission | 2.07e-05 | 7 | 21 | 2 | GO:0099183 | |
| GeneOntologyBiologicalProcess | RNA modification | 2.74e-05 | 176 | 21 | 4 | GO:0009451 | |
| GeneOntologyBiologicalProcess | trans-synaptic signaling by BDNF | 2.75e-05 | 8 | 21 | 2 | GO:0099191 | |
| GeneOntologyBiologicalProcess | regulation of viral process | 3.40e-05 | 186 | 21 | 4 | GO:0050792 | |
| GeneOntologyBiologicalProcess | proteoglycan catabolic process | 5.40e-05 | 11 | 21 | 2 | GO:0030167 | |
| GeneOntologyBiologicalProcess | negative regulation of fibrinolysis | 8.92e-05 | 14 | 21 | 2 | GO:0051918 | |
| GeneOntologyBiologicalProcess | positive regulation of gene expression via chromosomal CpG island demethylation | 1.03e-04 | 15 | 21 | 2 | GO:0044029 | |
| GeneOntologyBiologicalProcess | carbohydrate derivative metabolic process | 1.43e-04 | 1226 | 21 | 7 | GO:1901135 | |
| GeneOntologyBiologicalProcess | regulation of fibrinolysis | 1.67e-04 | 19 | 21 | 2 | GO:0051917 | |
| GeneOntologyBiologicalProcess | embryonic placenta development | 2.31e-04 | 119 | 21 | 3 | GO:0001892 | |
| GeneOntologyBiologicalProcess | trans-synaptic signaling, modulating synaptic transmission | 3.16e-04 | 26 | 21 | 2 | GO:0099550 | |
| GeneOntologyBiologicalProcess | biological process involved in interaction with symbiont | 3.35e-04 | 135 | 21 | 3 | GO:0051702 | |
| GeneOntologyBiologicalProcess | viral life cycle | 3.48e-04 | 340 | 21 | 4 | GO:0019058 | |
| GeneOntologyBiologicalProcess | defense response to virus | 3.56e-04 | 342 | 21 | 4 | GO:0051607 | |
| GeneOntologyBiologicalProcess | fibrinolysis | 3.94e-04 | 29 | 21 | 2 | GO:0042730 | |
| GeneOntologyBiologicalProcess | labyrinthine layer blood vessel development | 3.94e-04 | 29 | 21 | 2 | GO:0060716 | |
| GeneOntologyBiologicalProcess | positive regulation of hemostasis | 4.51e-04 | 31 | 21 | 2 | GO:1900048 | |
| GeneOntologyBiologicalProcess | positive regulation of blood coagulation | 4.51e-04 | 31 | 21 | 2 | GO:0030194 | |
| GeneOntologyBiologicalProcess | muscle cell cellular homeostasis | 4.51e-04 | 31 | 21 | 2 | GO:0046716 | |
| GeneOntologyBiologicalProcess | positive regulation of coagulation | 5.43e-04 | 34 | 21 | 2 | GO:0050820 | |
| GeneOntologyBiologicalProcess | small molecule catabolic process | 7.77e-04 | 421 | 21 | 4 | GO:0044282 | |
| GeneOntologyBiologicalProcess | glycoprotein catabolic process | 7.90e-04 | 41 | 21 | 2 | GO:0006516 | |
| GeneOntologyBiologicalProcess | response to virus | 8.05e-04 | 425 | 21 | 4 | GO:0009615 | |
| GeneOntologyBiologicalProcess | placenta blood vessel development | 9.10e-04 | 44 | 21 | 2 | GO:0060674 | |
| GeneOntologyBiologicalProcess | placenta development | 1.01e-03 | 197 | 21 | 3 | GO:0001890 | |
| GeneOntologyBiologicalProcess | viral process | 1.12e-03 | 464 | 21 | 4 | GO:0016032 | |
| GeneOntologyBiologicalProcess | labyrinthine layer development | 1.92e-03 | 64 | 21 | 2 | GO:0060711 | |
| GeneOntologyBiologicalProcess | transcription initiation-coupled chromatin remodeling | 1.98e-03 | 65 | 21 | 2 | GO:0045815 | |
| GeneOntologyBiologicalProcess | positive regulation of gene expression, epigenetic | 2.16e-03 | 68 | 21 | 2 | GO:0141137 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 2.22e-03 | 69 | 21 | 2 | GO:0030195 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 2.29e-03 | 70 | 21 | 2 | GO:1900047 | |
| GeneOntologyBiologicalProcess | negative regulation of coagulation | 2.42e-03 | 72 | 21 | 2 | GO:0050819 | |
| GeneOntologyBiologicalProcess | positive regulation of wound healing | 2.48e-03 | 73 | 21 | 2 | GO:0090303 | |
| GeneOntologyBiologicalProcess | negative regulation of cell-substrate adhesion | 2.55e-03 | 74 | 21 | 2 | GO:0010812 | |
| GeneOntologyBiologicalProcess | extracellular matrix disassembly | 2.62e-03 | 75 | 21 | 2 | GO:0022617 | |
| GeneOntologyBiologicalProcess | positive regulation of blood vessel endothelial cell migration | 3.51e-03 | 87 | 21 | 2 | GO:0043536 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 3.83e-03 | 91 | 21 | 2 | GO:0030193 | |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 3.99e-03 | 93 | 21 | 2 | GO:1900046 | |
| GeneOntologyBiologicalProcess | positive regulation of response to wounding | 3.99e-03 | 93 | 21 | 2 | GO:1903036 | |
| GeneOntologyBiologicalProcess | regulation of coagulation | 4.25e-03 | 96 | 21 | 2 | GO:0050818 | |
| GeneOntologyBiologicalProcess | proteoglycan metabolic process | 4.34e-03 | 97 | 21 | 2 | GO:0006029 | |
| GeneOntologyBiologicalProcess | negative regulation of wound healing | 4.42e-03 | 98 | 21 | 2 | GO:0061045 | |
| GeneOntologyBiologicalProcess | tissue regeneration | 4.51e-03 | 99 | 21 | 2 | GO:0042246 | |
| GeneOntologyBiologicalProcess | protein lipidation | 4.69e-03 | 101 | 21 | 2 | GO:0006497 | |
| GeneOntologyBiologicalProcess | nucleobase-containing compound catabolic process | 4.87e-03 | 696 | 21 | 4 | GO:0034655 | |
| GeneOntologyCellularComponent | P-body | 4.41e-06 | 102 | 23 | 4 | GO:0000932 | |
| GeneOntologyCellularComponent | cytoplasmic ribonucleoprotein granule | 1.96e-04 | 269 | 23 | 4 | GO:0036464 | |
| GeneOntologyCellularComponent | ribonucleoprotein granule | 2.51e-04 | 287 | 23 | 4 | GO:0035770 | |
| GeneOntologyCellularComponent | external side of plasma membrane | 2.29e-03 | 519 | 23 | 4 | GO:0009897 | |
| MousePheno | lactation failure | 6.74e-07 | 17 | 15 | 3 | MP:0010249 | |
| MousePheno | esophageal ulcer | 1.07e-06 | 2 | 15 | 2 | MP:0004547 | |
| MousePheno | duodenal ulcer | 1.07e-06 | 2 | 15 | 2 | MP:0003273 | |
| MousePheno | abnormal mammary gland connective tissue morphology | 1.07e-06 | 2 | 15 | 2 | MP:0009507 | |
| MousePheno | perianal ulcer | 1.07e-06 | 2 | 15 | 2 | MP:0005035 | |
| MousePheno | ectropion | 1.07e-06 | 2 | 15 | 2 | MP:0006164 | |
| MousePheno | absent cornea epithelium | 3.22e-06 | 3 | 15 | 2 | MP:0020856 | |
| MousePheno | increased circulating fibrinogen level | 6.44e-06 | 4 | 15 | 2 | MP:0012331 | |
| MousePheno | proctitis | 6.44e-06 | 4 | 15 | 2 | MP:0003305 | |
| MousePheno | gastric ulcer | 1.61e-05 | 6 | 15 | 2 | MP:0003282 | |
| MousePheno | increased acute phase protein level | 2.25e-05 | 7 | 15 | 2 | MP:0014499 | |
| MousePheno | abnormal conjunctival epithelium morphology | 2.25e-05 | 7 | 15 | 2 | MP:0004481 | |
| MousePheno | venoocclusion | 2.25e-05 | 7 | 15 | 2 | MP:0006137 | |
| MousePheno | peptic ulcer | 2.25e-05 | 7 | 15 | 2 | MP:0003301 | |
| MousePheno | decreased keratinocyte migration | 3.00e-05 | 8 | 15 | 2 | MP:0012194 | |
| MousePheno | abnormal circulating fibrinogen level | 3.00e-05 | 8 | 15 | 2 | MP:0010213 | |
| MousePheno | abnormal kidney thrombosis | 4.81e-05 | 10 | 15 | 2 | MP:0011507 | |
| MousePheno | decreased susceptibility to induced choroidal neovascularization | 4.81e-05 | 10 | 15 | 2 | MP:0003434 | |
| MousePheno | abnormal lactation | 5.70e-05 | 72 | 15 | 3 | MP:0001882 | |
| MousePheno | abnormal keratinocyte migration | 5.88e-05 | 11 | 15 | 2 | MP:0012192 | |
| MousePheno | abnormal anus morphology | 8.33e-05 | 13 | 15 | 2 | MP:0005034 | |
| MousePheno | abnormal conjunctiva morphology | 8.33e-05 | 13 | 15 | 2 | MP:0001310 | |
| MousePheno | abnormal mammary gland physiology | 1.04e-04 | 88 | 15 | 3 | MP:0001881 | |
| MousePheno | abnormal apocrine gland physiology | 1.04e-04 | 88 | 15 | 3 | MP:0013555 | |
| MousePheno | increased hepatocyte proliferation | 1.45e-04 | 17 | 15 | 2 | MP:0003893 | |
| MousePheno | choroidal neovascularization | 1.82e-04 | 19 | 15 | 2 | MP:0005546 | |
| MousePheno | abnormal tumor morphology | 2.73e-04 | 122 | 15 | 3 | MP:0003448 | |
| MousePheno | abnormal involution of the mammary gland | 2.93e-04 | 24 | 15 | 2 | MP:0006271 | |
| MousePheno | intestinal ulcer | 2.93e-04 | 24 | 15 | 2 | MP:0000512 | |
| MousePheno | abnormal mammary gland development | 3.01e-04 | 126 | 15 | 3 | MP:0000628 | |
| MousePheno | abnormal acute phase protein level | 3.18e-04 | 25 | 15 | 2 | MP:0010211 | |
| MousePheno | conjunctivitis | 3.44e-04 | 26 | 15 | 2 | MP:0001852 | |
| MousePheno | abnormal choroid vasculature morphology | 3.71e-04 | 27 | 15 | 2 | MP:0006237 | |
| MousePheno | abnormal anal canal morphology | 3.71e-04 | 27 | 15 | 2 | MP:0009053 | |
| MousePheno | abnormal mammary gland growth during lactation | 4.00e-04 | 28 | 15 | 2 | MP:0006270 | |
| MousePheno | rectal prolapse | 4.29e-04 | 29 | 15 | 2 | MP:0000493 | |
| MousePheno | gastrointestinal ulcer | 4.91e-04 | 31 | 15 | 2 | MP:0003300 | |
| MousePheno | abnormal skin adnexa physiology | 6.86e-04 | 167 | 15 | 3 | MP:0010680 | |
| MousePheno | decreased susceptibility to neuronal excitotoxicity | 7.00e-04 | 37 | 15 | 2 | MP:0008236 | |
| MousePheno | abnormal cornea stroma morphology | 7.39e-04 | 38 | 15 | 2 | MP:0005300 | |
| MousePheno | abnormal tumor pathology | 7.99e-04 | 176 | 15 | 3 | MP:0010639 | |
| MousePheno | abnormal skin adnexa development | 8.12e-04 | 177 | 15 | 3 | MP:0020982 | |
| MousePheno | abnormal larynx morphology | 8.19e-04 | 40 | 15 | 2 | MP:0002249 | |
| MousePheno | abnormal cornea epithelium morphology | 9.03e-04 | 42 | 15 | 2 | MP:0006000 | |
| MousePheno | impaired wound healing | 9.03e-04 | 42 | 15 | 2 | MP:0001792 | |
| MousePheno | abnormal rectum morphology | 9.46e-04 | 43 | 15 | 2 | MP:0000492 | |
| MousePheno | abnormal exocrine gland physiology | 1.09e-03 | 196 | 15 | 3 | MP:0013559 | |
| MousePheno | abnormal macrophage physiology | 1.10e-03 | 451 | 15 | 4 | MP:0002451 | |
| MousePheno | abnormal mammary gland morphology | 1.17e-03 | 201 | 15 | 3 | MP:0000627 | |
| MousePheno | abnormal apocrine gland morphology | 1.17e-03 | 201 | 15 | 3 | MP:0013554 | |
| MousePheno | cornea vascularization | 1.23e-03 | 49 | 15 | 2 | MP:0005542 | |
| MousePheno | impaired macrophage phagocytosis | 1.28e-03 | 50 | 15 | 2 | MP:0001798 | |
| MousePheno | pulmonary fibrosis | 1.33e-03 | 51 | 15 | 2 | MP:0006050 | |
| MousePheno | abnormal vagina morphology | 1.33e-03 | 51 | 15 | 2 | MP:0001139 | |
| MousePheno | abnormal optic choroid morphology | 1.38e-03 | 52 | 15 | 2 | MP:0005098 | |
| MousePheno | abnormal gland development | 1.79e-03 | 233 | 15 | 3 | MP:0020973 | |
| MousePheno | eye hemorrhage | 1.84e-03 | 60 | 15 | 2 | MP:0006203 | |
| MousePheno | abnormal blood coagulation | 1.95e-03 | 240 | 15 | 3 | MP:0002551 | |
| MousePheno | abnormal hemostasis | 2.00e-03 | 242 | 15 | 3 | MP:0009676 | |
| MousePheno | abnormal microglial cell physiology | 2.02e-03 | 63 | 15 | 2 | MP:0003691 | |
| MousePheno | abnormal duodenum morphology | 2.08e-03 | 64 | 15 | 2 | MP:0003271 | |
| MousePheno | decreased tumor growth/size | 2.08e-03 | 64 | 15 | 2 | MP:0003447 | |
| MousePheno | decreased cell migration | 2.15e-03 | 65 | 15 | 2 | MP:0011805 | |
| MousePheno | blood vessel congestion | 2.15e-03 | 65 | 15 | 2 | MP:0000255 | |
| MousePheno | abnormal esophagus morphology | 2.22e-03 | 66 | 15 | 2 | MP:0000467 | |
| MousePheno | abnormal ocular surface morphology | 2.28e-03 | 67 | 15 | 2 | MP:0013754 | |
| MousePheno | eye inflammation | 2.70e-03 | 73 | 15 | 2 | MP:0001851 | |
| MousePheno | decreased neuron apoptosis | 2.70e-03 | 73 | 15 | 2 | MP:0003204 | |
| MousePheno | liver fibrosis | 3.00e-03 | 77 | 15 | 2 | MP:0003333 | |
| MousePheno | abnormal stomach mucosa morphology | 3.00e-03 | 77 | 15 | 2 | MP:0010792 | |
| MousePheno | abnormal professional antigen presenting cell physiology | 3.09e-03 | 1004 | 15 | 5 | MP:0002452 | |
| MousePheno | abnormal digestive system physiology | 3.12e-03 | 599 | 15 | 4 | MP:0001663 | |
| MousePheno | hepatic necrosis | 3.16e-03 | 79 | 15 | 2 | MP:0001654 | |
| MousePheno | abnormal stomach wall morphology | 3.24e-03 | 80 | 15 | 2 | MP:0010783 | |
| MousePheno | abnormal keratinocyte physiology | 3.32e-03 | 81 | 15 | 2 | MP:0003453 | |
| MousePheno | abnormal trachea morphology | 3.32e-03 | 81 | 15 | 2 | MP:0002282 | |
| MousePheno | reduced female fertility | 3.54e-03 | 296 | 15 | 3 | MP:0001923 | |
| MousePheno | decreased angiogenesis | 3.56e-03 | 84 | 15 | 2 | MP:0005602 | |
| MousePheno | abnormal innate immunity | 4.60e-03 | 667 | 15 | 4 | MP:0002419 | |
| MousePheno | abnormal lymph node morphology | 5.01e-03 | 683 | 15 | 4 | MP:0002339 | |
| MousePheno | abnormal glial cell physiology | 5.20e-03 | 102 | 15 | 2 | MP:0003690 | |
| MousePheno | increased susceptibility to bacterial infection induced morbidity/mortality | 5.20e-03 | 102 | 15 | 2 | MP:0009788 | |
| MousePheno | decreased susceptibility to induced morbidity/mortality | 5.61e-03 | 106 | 15 | 2 | MP:0009764 | |
| MousePheno | abnormal thrombosis | 5.61e-03 | 106 | 15 | 2 | MP:0005048 | |
| MousePheno | pathological neovascularization | 5.82e-03 | 108 | 15 | 2 | MP:0003711 | |
| Domain | APOBEC_N | 8.59e-10 | 12 | 23 | 4 | IPR013158 | |
| Domain | APOBEC_N | 8.59e-10 | 12 | 23 | 4 | PF08210 | |
| Domain | APOBEC/CMP_deaminase_Zn-bd | 1.73e-09 | 14 | 23 | 4 | IPR016192 | |
| Domain | CYT_DCMP_DEAMINASES_2 | 2.36e-09 | 15 | 23 | 4 | PS51747 | |
| Domain | CMP_dCMP_Zn-bd | 4.11e-09 | 17 | 23 | 4 | IPR002125 | |
| Domain | CYT_DCMP_DEAMINASES_1 | 4.11e-09 | 17 | 23 | 4 | PS00903 | |
| Domain | Cytidine_deaminase-like | 4.11e-09 | 17 | 23 | 4 | IPR016193 | |
| Domain | Kringle | 1.95e-04 | 17 | 23 | 2 | IPR000001 | |
| Domain | KRINGLE_1 | 1.95e-04 | 17 | 23 | 2 | PS00021 | |
| Domain | Kringle_CS | 1.95e-04 | 17 | 23 | 2 | IPR018056 | |
| Domain | Kringle | 1.95e-04 | 17 | 23 | 2 | PF00051 | |
| Domain | KR | 1.95e-04 | 17 | 23 | 2 | SM00130 | |
| Domain | KRINGLE_2 | 1.95e-04 | 17 | 23 | 2 | PS50070 | |
| Domain | Kringle-like | 7.04e-04 | 32 | 23 | 2 | IPR013806 | |
| Domain | ZINC_PROTEASE | 6.42e-03 | 98 | 23 | 2 | PS00142 | |
| Domain | TRYPSIN_HIS | 7.07e-03 | 103 | 23 | 2 | IPR018114 | |
| Domain | TRYPSIN_SER | 7.47e-03 | 106 | 23 | 2 | PS00135 | |
| Domain | TRYPSIN_HIS | 7.61e-03 | 107 | 23 | 2 | PS00134 | |
| Domain | Peptidase_S1A | 8.45e-03 | 113 | 23 | 2 | IPR001314 | |
| Domain | TRYPSIN_DOM | 8.74e-03 | 115 | 23 | 2 | PS50240 | |
| Domain | Tryp_SPc | 9.03e-03 | 117 | 23 | 2 | SM00020 | |
| Domain | Trypsin | 9.64e-03 | 121 | 23 | 2 | PF00089 | |
| Domain | Trypsin_dom | 9.64e-03 | 121 | 23 | 2 | IPR001254 | |
| Domain | Peptidase_S1_PA | 9.94e-03 | 123 | 23 | 2 | IPR009003 | |
| Pathway | REACTOME_MRNA_EDITING_C_TO_U_CONVERSION | 5.33e-05 | 8 | 20 | 2 | M27683 | |
| Pathway | REACTOME_MRNA_EDITING | 8.55e-05 | 10 | 20 | 2 | M27709 | |
| Pathway | BIOCARTA_FIBRINOLYSIS_PATHWAY | 1.25e-04 | 12 | 20 | 2 | MM1398 | |
| Pathway | BIOCARTA_PLATELETAPP_PATHWAY | 1.72e-04 | 14 | 20 | 2 | MM1458 | |
| Pathway | REACTOME_DISSOLUTION_OF_FIBRIN_CLOT | 1.99e-04 | 15 | 20 | 2 | MM15450 | |
| Pathway | WP_BDNF_PATHWAY | 2.27e-04 | 16 | 20 | 2 | MM15816 | |
| Pathway | WP_BLOOD_CLOTTING_CASCADE | 4.75e-04 | 23 | 20 | 2 | MM15936 | |
| Pathway | PID_RXR_VDR_PATHWAY | 6.09e-04 | 26 | 20 | 2 | M162 | |
| Pathway | REACTOME_ACTIVATION_OF_MATRIX_METALLOPROTEINASES | 1.30e-03 | 38 | 20 | 2 | MM14611 | |
| Pathway | PID_AMB2_NEUTROPHILS_PATHWAY | 1.52e-03 | 41 | 20 | 2 | M159 | |
| Pathway | WP_FIBRIN_COMPLEMENT_RECEPTOR_3_SIGNALING_PATHWAY | 2.07e-03 | 48 | 20 | 2 | MM15897 | |
| Pubmed | 4.78e-11 | 11 | 23 | 4 | 12683974 | ||
| Pubmed | Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. | 2.53e-10 | 3 | 23 | 3 | 18420796 | |
| Pubmed | 2.53e-10 | 3 | 23 | 3 | 31400856 | ||
| Pubmed | 1.01e-09 | 4 | 23 | 3 | 23787464 | ||
| Pubmed | 2.52e-09 | 5 | 23 | 3 | 25461536 | ||
| Pubmed | AID and APOBECs span the gap between innate and adaptive immunity. | 2.52e-09 | 5 | 23 | 3 | 25352838 | |
| Pubmed | 5.05e-09 | 6 | 23 | 3 | 22205746 | ||
| Pubmed | Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. | 5.05e-09 | 6 | 23 | 3 | 22912627 | |
| Pubmed | Structure-guided analysis of the human APOBEC3-HIV restrictome. | 5.05e-09 | 6 | 23 | 3 | 24657093 | |
| Pubmed | 8.83e-09 | 7 | 23 | 3 | 21835787 | ||
| Pubmed | 1.41e-08 | 8 | 23 | 3 | 24227842 | ||
| Pubmed | The assembly of Vif ubiquitin E3 ligase for APOBEC3 degradation. | 2.12e-08 | 9 | 23 | 3 | 25408426 | |
| Pubmed | 3.02e-08 | 10 | 23 | 3 | 23043103 | ||
| Pubmed | Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. | 3.02e-08 | 10 | 23 | 3 | 20174454 | |
| Pubmed | HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. | 4.15e-08 | 11 | 23 | 3 | 22915799 | |
| Pubmed | Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. | 1.71e-07 | 17 | 23 | 3 | 24189052 | |
| Pubmed | Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. | 2.05e-07 | 18 | 23 | 3 | 20096141 | |
| Pubmed | Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function. | 4.18e-07 | 2 | 23 | 2 | 21239499 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 31690812 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 30254165 | ||
| Pubmed | Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. | 4.18e-07 | 2 | 23 | 2 | 18495196 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 10642175 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 12225871 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 9770530 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 38328826 | ||
| Pubmed | Determinants of sequence-specificity within human AID and APOBEC3G. | 4.18e-07 | 2 | 23 | 2 | 20338830 | |
| Pubmed | Reduced transplant arteriosclerosis in plasminogen-deficient mice. | 4.18e-07 | 2 | 23 | 2 | 9819364 | |
| Pubmed | Plasminogen activation is required for the development of radiation-induced dermatitis. | 4.18e-07 | 2 | 23 | 2 | 30323258 | |
| Pubmed | Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression. | 4.18e-07 | 2 | 23 | 2 | 37971174 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 17161027 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 9884337 | ||
| Pubmed | Persistent corneal haze after excimer laser photokeratectomy in plasminogen-deficient mice. | 4.18e-07 | 2 | 23 | 2 | 10634603 | |
| Pubmed | Colonic Lesions, Cytokine Profiles, and Gut Microbiota in Plasminogen-Deficient Mice. | 4.18e-07 | 2 | 23 | 2 | 26473342 | |
| Pubmed | Thrombomodulin functions as a plasminogen receptor to modulate angiogenesis. | 4.18e-07 | 2 | 23 | 2 | 23943648 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 12083480 | ||
| Pubmed | Polymorphonuclear leukocyte phagocytic function increases in plasminogen knockout mice. | 4.18e-07 | 2 | 23 | 2 | 18420257 | |
| Pubmed | Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. | 4.18e-07 | 2 | 23 | 2 | 7705657 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 10816371 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 23041318 | ||
| Pubmed | Plasminogen alleles influence susceptibility to invasive aspergillosis. | 4.18e-07 | 2 | 23 | 2 | 18566672 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 19752236 | ||
| Pubmed | Plasminogen is a critical regulator of cutaneous wound healing. | 4.18e-07 | 2 | 23 | 2 | 26791370 | |
| Pubmed | Selection of mutant µplasmin for amyloid-β cleavage in vivo. | 4.18e-07 | 2 | 23 | 2 | 32694536 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 7525077 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 6216475 | ||
| Pubmed | Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. | 4.18e-07 | 2 | 23 | 2 | 16052596 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 17122079 | ||
| Pubmed | The generation and characterization of mice expressing a plasmin-inactivating active site mutation. | 4.18e-07 | 2 | 23 | 2 | 20653841 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 12428098 | ||
| Pubmed | Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. | 4.18e-07 | 2 | 23 | 2 | 20440070 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 16103174 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 24732409 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 21300353 | ||
| Pubmed | A central role for plasminogen in the inflammatory response to biomaterials. | 4.18e-07 | 2 | 23 | 2 | 15456492 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 24876560 | ||
| Pubmed | Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice. | 4.18e-07 | 2 | 23 | 2 | 24574269 | |
| Pubmed | Spontaneous development of otitis media in plasminogen-deficient mice. | 4.18e-07 | 2 | 23 | 2 | 16956791 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 25409527 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 15737740 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 11306011 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 1543918 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 12149246 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 8704243 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 22056679 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 17267741 | ||
| Pubmed | Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis. | 4.18e-07 | 2 | 23 | 2 | 18311818 | |
| Pubmed | Localization of plasminogen in mouse hippocampus, cerebral cortex, and hypothalamus. | 4.18e-07 | 2 | 23 | 2 | 21190118 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 18039665 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 9671388 | ||
| Pubmed | A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response. | 4.18e-07 | 2 | 23 | 2 | 18997104 | |
| Pubmed | Growth and behavioral development in plasminogen gene-targeted mice. | 4.18e-07 | 2 | 23 | 2 | 10885855 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 23702659 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 29990619 | ||
| Pubmed | Cellular density regulation of plasminogen gene expression in mouse hepatocytes. | 4.18e-07 | 2 | 23 | 2 | 12559391 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 17293777 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 27319402 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 18391217 | ||
| Pubmed | Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. | 4.18e-07 | 2 | 23 | 2 | 15333838 | |
| Pubmed | Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen. | 4.18e-07 | 2 | 23 | 2 | 16150044 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 11916082 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 23456978 | ||
| Pubmed | Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. | 4.18e-07 | 2 | 23 | 2 | 10854210 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 18827027 | ||
| Pubmed | Unaltered prion protein cleavage in plasminogen-deficient mice. | 4.18e-07 | 2 | 23 | 2 | 16543819 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 34423816 | ||
| Pubmed | Delayed invasion of the kidney and brain by Borrelia crocidurae in plasminogen-deficient mice. | 4.18e-07 | 2 | 23 | 2 | 11500461 | |
| Pubmed | Gender affects skin wound healing in plasminogen deficient mice. | 4.18e-07 | 2 | 23 | 2 | 23527289 | |
| Pubmed | Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation. | 4.18e-07 | 2 | 23 | 2 | 22079981 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 12167431 | ||
| Pubmed | Impaired wound healing in mice with a disrupted plasminogen gene. | 4.18e-07 | 2 | 23 | 2 | 8612226 | |
| Pubmed | Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. | 4.18e-07 | 2 | 23 | 2 | 16571802 | |
| Pubmed | Role of plasminogen activation in neuronal organization and survival. | 4.18e-07 | 2 | 23 | 2 | 19683575 | |
| Pubmed | Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. | 4.18e-07 | 2 | 23 | 2 | 9490683 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 10537128 | ||
| Pubmed | Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. | 4.18e-07 | 2 | 23 | 2 | 23555246 | |
| Pubmed | APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. | 4.18e-07 | 2 | 23 | 2 | 24361275 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 16481742 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 18983515 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 18685433 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 31462325 | ||
| Cytoband | Ensembl 112 genes in cytogenetic band chr6q26 | 2.87e-05 | 16 | 23 | 2 | chr6q26 | |
| Cytoband | 6q26 | 3.66e-05 | 18 | 23 | 2 | 6q26 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr22q13 | 5.86e-04 | 330 | 23 | 3 | chr22q13 | |
| Cytoband | 22q13.1 | 8.36e-04 | 85 | 23 | 2 | 22q13.1 | |
| GeneFamily | Apolipoprotein B mRNA editing enzyme catalytic subunits | 2.63e-10 | 12 | 17 | 4 | 406 | |
| Coexpression | GSE29949_MICROGLIA_BRAIN_VS_CD8_NEG_DC_SPLEEN_UP | 6.53e-07 | 195 | 23 | 5 | M8421 | |
| Coexpression | RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_UP | 1.10e-05 | 6 | 23 | 2 | MM555 | |
| ToppCell | (0)_NK/T_cells-(0)_T_CD8|(0)_NK/T_cells / Oesophagus cell shreds on cell class (v1) and cell subclass (v1) | 2.36e-05 | 109 | 23 | 3 | 73b188278473a3b112d406657680267b17a5b712 | |
| ToppCell | TCGA-Breast-Metastatic-Breast_Carcinoma-Infiltrating_Ductal_Carcinoma|TCGA-Breast / Sample_Type by Project: Shred V9 | 6.00e-05 | 149 | 23 | 3 | 2e9b898f3df22f8e872f2c278eff454c39e55b3b | |
| ToppCell | TCGA-Breast-Metastatic|TCGA-Breast / Sample_Type by Project: Shred V9 | 6.00e-05 | 149 | 23 | 3 | 144ac2c458209ce510674bc2f83eb4c8e4d3c953 | |
| ToppCell | TCGA-Breast-Metastatic-Breast_Carcinoma|TCGA-Breast / Sample_Type by Project: Shred V9 | 6.00e-05 | 149 | 23 | 3 | c7dc495141cd921b6b6f291a68851b7b807d0d0a | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell_cycling|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.75e-05 | 155 | 23 | 3 | 8b524c65fa5c901f70c7caae4ec7fd2859eaf227 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell_cycling-Cycling_Connecting_Tubule_Cell_low-phase|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.75e-05 | 155 | 23 | 3 | 7fe8b8c0c8a9e3190cfd52d3934509e6780e1717 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c11-GNLY|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 7.28e-05 | 159 | 23 | 3 | 57df5c9b678a15eb5e025e1a80de2e6769cc13d5 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell-CD8_T_cells-CD8_T_cells_L.1.1.2.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.98e-05 | 164 | 23 | 3 | 30c3c25b05a403a509b2e755c2f0878fecb10a02 | |
| ToppCell | Club-club-12|World / Class top | 8.13e-05 | 165 | 23 | 3 | 9b7a31cbdcd2f96b8bd08a4cd4141b92bd5e9062 | |
| ToppCell | droplet-Thymus-nan-24m-Lymphocytic-DN_to_DP_transition,_dividing_(more_DN)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.57e-05 | 168 | 23 | 3 | b9db0b1e4fe54a1fe79530d15d206155a1bfac39 | |
| ToppCell | 343B-Lymphocytic-NK_cells-NK_cell_B2|343B / Donor, Lineage, Cell class and subclass (all cells) | 9.03e-05 | 171 | 23 | 3 | d1c5540e59c64eb233acab53bfd0d68e922a74bb | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-Cytotoxic_CD8+_T|normal_Pleural_Fluid / Location, Cell class and cell subclass | 9.03e-05 | 171 | 23 | 3 | 6be81c20f4e962b414afcedfe478dd59c510d1e1 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_ILC|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.51e-05 | 174 | 23 | 3 | e70cc623a3a6aceec813ed852fec0c4240561133 | |
| ToppCell | TCGA-Liver|World / Sample_Type by Project: Shred V9 | 9.51e-05 | 174 | 23 | 3 | 452932f08cf53e5949672a025d78cecb874aa4b0 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_ILC-NK_cell|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.51e-05 | 174 | 23 | 3 | b6725086fe5a2b057c7c495ec63c970ac52c2580 | |
| ToppCell | TCGA-Prostate-Solid_Tissue_Normal-Prostate_normal_tissue-Prostate_normal_tissue|TCGA-Prostate / Sample_Type by Project: Shred V9 | 9.51e-05 | 174 | 23 | 3 | de6c1ebca36ec8060ddcafc270c45d6ab1caec2c | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.51e-05 | 174 | 23 | 3 | 9bb8159a62640756d18ecbade3bf32bcbb7dd590 | |
| ToppCell | TCGA-Prostate-Solid_Tissue_Normal|TCGA-Prostate / Sample_Type by Project: Shred V9 | 9.51e-05 | 174 | 23 | 3 | abdb5a89118b82bb64469fc41c163bd2b282b0c0 | |
| ToppCell | TCGA-Prostate-Solid_Tissue_Normal-Prostate_normal_tissue|TCGA-Prostate / Sample_Type by Project: Shred V9 | 9.51e-05 | 174 | 23 | 3 | 0dde0e9ef987c52cb29a238f15568a83424d02f6 | |
| ToppCell | TCGA-Colorectal-Recurrent_Tumor|TCGA-Colorectal / Sample_Type by Project: Shred V9 | 9.67e-05 | 175 | 23 | 3 | 7f74961436f88c0e380819095e6104489914d765 | |
| ToppCell | TCGA-Colorectal-Recurrent_Tumor-Colorectal_Adenocarcinoma|TCGA-Colorectal / Sample_Type by Project: Shred V9 | 9.67e-05 | 175 | 23 | 3 | bee8f31f036dfcf9fc6ed29156554771a9ee3c60 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.03e-04 | 179 | 23 | 3 | d1ef7e1cb00336118e387b47f4f8120f53584391 | |
| ToppCell | IIH-CD4-exh_CD4|IIH / Condition, Cell_class and T cell subcluster | 1.05e-04 | 180 | 23 | 3 | 31f22960819bfad79cbbd3b10c5dc46d7a47e340 | |
| ToppCell | lymphoid-T_cell-CD8+_Effector_T_cell|World / Lineage, cell class and subclass | 1.07e-04 | 181 | 23 | 3 | de4c5b043d743a93f2b0864b178aed0947b9af62 | |
| ToppCell | lymphoid-T_cell-CD8+_Effector_T_cell|lymphoid / Lineage, cell class and subclass | 1.09e-04 | 182 | 23 | 3 | d4ef4a7c0f5dc044eb5cc6c0bcf539c88b1b4fef | |
| ToppCell | normal_Lung-T/NK_cells-Exhausted_CD8+_T|normal_Lung / Location, Cell class and cell subclass | 1.10e-04 | 183 | 23 | 3 | a2901707d0f0900ff91c08c9152dad0b6c191cca | |
| ToppCell | lymphoid-T_cell-CD8+_Effector_T_cell|T_cell / Lineage, cell class and subclass | 1.12e-04 | 184 | 23 | 3 | f610f28f8319d194871a3e94210bf1c493918986 | |
| ToppCell | Control-Lymphoid-CD8_T_cells|Lymphoid / Condition, Lineage and Cell class | 1.16e-04 | 186 | 23 | 3 | a8a4c0f4058f5bbc435dd2dd41d55383173a1358 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.16e-04 | 186 | 23 | 3 | b1edc341d6684b347dc9e21b34f62f51d095d735 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.18e-04 | 187 | 23 | 3 | d17352f769c3c66601b65d060626eecff41b0482 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.18e-04 | 187 | 23 | 3 | 8c69fd469df2915c56ede534cee3ef23d5f64ebf | |
| ToppCell | NS-critical-d_16-33-Lymphoid-CTL|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.21e-04 | 189 | 23 | 3 | 8a02c40bfc92cee37c4dee7c7bf98ab826f64a14 | |
| ToppCell | metastatic_Lymph_Node-T/NK_cells-Exhausted_CD8+_T|metastatic_Lymph_Node / Location, Cell class and cell subclass | 1.23e-04 | 190 | 23 | 3 | cb4cf8ae2156c20b7978ae2e55aa605b4e90f455 | |
| ToppCell | metastatic_Brain-T/NK_cells-Exhausted_CD8+_T|metastatic_Brain / Location, Cell class and cell subclass | 1.25e-04 | 191 | 23 | 3 | b98367fdb56ccb335d61035e69cd43c61a7fa816 | |
| ToppCell | metastatic_Lymph_Node-T/NK_cells-Exhausted_CD8+_T|T/NK_cells / Location, Cell class and cell subclass | 1.27e-04 | 192 | 23 | 3 | 5841378789d8267f94071df060debc9171700784 | |
| ToppCell | critical-Lymphoid-CTL|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 1.27e-04 | 192 | 23 | 3 | 8c83050c1578d43ca0398ff920f30ea63f092a83 | |
| ToppCell | NS-critical-d_07-13-Lymphoid-CTL|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.27e-04 | 192 | 23 | 3 | e7e5ba94ee8fd3c04bb4c358c86d0227c563e9dc | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-CD4/CD8-CD8_cytotoxic|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.29e-04 | 193 | 23 | 3 | 8c3771a6b81cf48a46a14c5c869ffc96fd996fb7 | |
| ToppCell | tumor_Lung-T/NK_cells-Exhausted_CD8+_T|T/NK_cells / Location, Cell class and cell subclass | 1.29e-04 | 193 | 23 | 3 | 3655b7d5ee055c0067764a70e4a0b4724e7a4e85 | |
| ToppCell | normal-na-Lymphocytic_T-CytoT_GZMH+-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 1.29e-04 | 193 | 23 | 3 | 3184a5f454e3ac5a81f6bacf9bd8f07d9d448fba | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c04-COTL1|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.29e-04 | 193 | 23 | 3 | 778fcf8448e81fe18972d97ea8a30ab036d16fe5 | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-Exhausted_CD8+_T|normal_Pleural_Fluid / Location, Cell class and cell subclass | 1.31e-04 | 194 | 23 | 3 | 68a9e00c9e1a855eeebfc26c038652f3800758db | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-NK-NK-Z|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.31e-04 | 194 | 23 | 3 | 6b5be379074241973220f7ef02ef3d5d7d8428ef | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.31e-04 | 194 | 23 | 3 | 64535db0420e53e4d777d2333b5051e63e8a3373 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-NK-NK|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.31e-04 | 194 | 23 | 3 | f6a655e1c2be2a326b934db0a5268e4db9112a74 | |
| ToppCell | tumor_Lung-T/NK_cells-Exhausted_CD8+_T|tumor_Lung / Location, Cell class and cell subclass | 1.31e-04 | 194 | 23 | 3 | 3fdcfd04174e39491d4f1e6276acc9d11e5a4345 | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-CD8_low_T|T/NK_cells / Location, Cell class and cell subclass | 1.31e-04 | 194 | 23 | 3 | cf2480cc40f3c9be837b3934547e2ce30bd4fcd3 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-NK|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.31e-04 | 194 | 23 | 3 | 4b3f400a5b7b8f999016e2daba50f65f4535b529 | |
| ToppCell | tumor_Lymph_Node_/_Brain-T/NK_cells-Exhausted_CD8+_T|T/NK_cells / Location, Cell class and cell subclass | 1.31e-04 | 194 | 23 | 3 | 7b8fe5b702b99aac5bff7de8ac0b5cabb3235b56 | |
| ToppCell | critical-Lymphoid-NKT|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 1.31e-04 | 194 | 23 | 3 | 6d47bb99157943fd1283f2e1bfa163ebe08c5a26 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-CD4/CD8-CD8_EM-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.31e-04 | 194 | 23 | 3 | c49f3341a19128855f084bcf18ef3da4bab79099 | |
| ToppCell | tumor_Lung-T/NK_cells-CD8_low_T|tumor_Lung / Location, Cell class and cell subclass | 1.31e-04 | 194 | 23 | 3 | 21d789585b3085aeeae3bef595c6cc5ea1c3dc4f | |
| ToppCell | tumor_Lymph_Node_/_Brain-T/NK_cells-Exhausted_CD8+_T|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass | 1.33e-04 | 195 | 23 | 3 | f2029195d5b655120a9e84074b2583e2d89c0a1d | |
| ToppCell | control-Lymphocytic-CD8_T_cells|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 1.33e-04 | 195 | 23 | 3 | 55b9052336cab3e769a126ecaeef267d8e7bcaa8 | |
| ToppCell | NS-critical-d_07-13-Lymphoid|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.33e-04 | 195 | 23 | 3 | 5222e0b753201a6a910efae193e5015bb32a3ede | |
| ToppCell | NS-critical-d_07-13-Lymphoid-NKT|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.33e-04 | 195 | 23 | 3 | f2693586c9e3c2ad1b5776f319b0b60e0c19628e | |
| ToppCell | T_cells-GZMK+_T_cells|T_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 1.33e-04 | 195 | 23 | 3 | 003ea7ddec6c1c98d2f6470bb51ebd97450eb936 | |
| ToppCell | moderate-Lymphoid-NKT|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 1.35e-04 | 196 | 23 | 3 | 12232b12bb6c7c993b3f81ce370517117e45a831 | |
| ToppCell | NS-moderate-d_16-33-Lymphoid-NKT|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.35e-04 | 196 | 23 | 3 | ea994e1d579b35877f0924404d31d55a940ec19b | |
| ToppCell | T_cells-GZMK+GZMB+_T_cells|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 1.35e-04 | 196 | 23 | 3 | b237287def04def371191b054a41ec0b3150da75 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c06-TNF|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.35e-04 | 196 | 23 | 3 | bc4628d959d76c16981ac3b943f7c3fbbba49391 | |
| ToppCell | MS-CD4-exh_CD4|MS / Condition, Cell_class and T cell subcluster | 1.35e-04 | 196 | 23 | 3 | d0217eccaa2cbf4ce9934e9d2e0c34a7f5c1a57e | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-CD4/CD8-CD8_EM|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.35e-04 | 196 | 23 | 3 | 8b63b29eb305fe05c967e47468318c60e9461a2d | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.35e-04 | 196 | 23 | 3 | 17f17edadafdad9f24e88d708d7e1c765503131c | |
| ToppCell | severe-Lymphocytic-CD8_T_cells|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 1.35e-04 | 196 | 23 | 3 | d83acd9abd7b296989b8ae09da63799e6877a149 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c11-GNLY|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.37e-04 | 197 | 23 | 3 | 1ca06d6d288cb58a6e8062ebc01831e58ee5be4b | |
| ToppCell | mild-Lymphocytic-CD8_T_cells|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 1.37e-04 | 197 | 23 | 3 | 8b0e4012e25641c3bcd3e9911031e43d9dbbff21 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-CD8_cytotoxic-Z|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.37e-04 | 197 | 23 | 3 | d0962c94f4b07759b0c9dade75c39fd2deec2f21 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c04-COTL1|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.37e-04 | 197 | 23 | 3 | 8e41e6cda38eace961cb1a56f4df24468c66b956 | |
| ToppCell | CV-Moderate|CV / Virus stimulation, Condition and Cluster | 1.37e-04 | 197 | 23 | 3 | 8747a57ded96175a8365f066101ce2af80c8081d | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-Exhausted_CD8+_T|T/NK_cells / Location, Cell class and cell subclass | 1.37e-04 | 197 | 23 | 3 | 2bf540fa228687a71f595a807e4a2af20588a82c | |
| ToppCell | CV-Moderate-3|CV / Virus stimulation, Condition and Cluster | 1.37e-04 | 197 | 23 | 3 | 7031286e300eaccf73b927939f8de3a9d2d5fc74 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-Prolif_T-G|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.39e-04 | 198 | 23 | 3 | beebbf637221021686e932c3d1bbf0f62cf95536 | |
| ToppCell | Caecum-(1)_T_cell-(18)_cycling_gd_T|Caecum / shred on region, Cell_type, and subtype | 1.39e-04 | 198 | 23 | 3 | 64278d8831c81874937e76b561c53928dfc437c5 | |
| ToppCell | Caecum-T_cell-cycling_gd_T|Caecum / Region, Cell class and subclass | 1.39e-04 | 198 | 23 | 3 | 5b719b67f8384863077070e1eb7e04a320e6dab4 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c11-GNLY|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.39e-04 | 198 | 23 | 3 | a6b942fe850e287e1cb705684e29218072daf891 | |
| ToppCell | T_cells-GZMK+GZMB+_T_cells|T_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 1.39e-04 | 198 | 23 | 3 | 085ba270f9defbf5ef45108c6d870e1d7c428479 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-Prolif_T-Z|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.41e-04 | 199 | 23 | 3 | 75f221c99adaa29f45dbe365f638b8b123eea148 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.41e-04 | 199 | 23 | 3 | 33b69b7b1542cc826380cb4f2629c422b7f85c9a | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-Prolif_T|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.41e-04 | 199 | 23 | 3 | ef767641b669eb2ef3461e51548f4dd09292de90 | |
| ToppCell | Control_saline-Epithelial_airway-airway_epithelial-Airway-Club|Control_saline / Treatment groups by lineage, cell group, cell type | 1.41e-04 | 199 | 23 | 3 | 5cc8b553a58669a30eb10845beb23983dcdf5a6a | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-CD8_cytotoxic|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.41e-04 | 199 | 23 | 3 | 017d67582f80d90f20b3d02044fa2e32f3dff289 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.41e-04 | 199 | 23 | 3 | 44ea9c41a20252fae403f993f6646c2f4073c23d | |
| ToppCell | Parenchymal-10x3prime_v2-Epithelial-Epi_airway_basal-Dividing_Basal|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 1.41e-04 | 199 | 23 | 3 | f0c289523957258d16135c04679db379d43d28d9 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.44e-04 | 200 | 23 | 3 | 2bd8c35484fe6b0bc0f9314216786baaa97d1e95 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 1.44e-04 | 200 | 23 | 3 | bd8cf33502adea320e91ca2af14e1911d88ad374 | |
| ToppCell | Club-club-11|World / Class top | 3.65e-04 | 55 | 23 | 2 | d1d832e1c98a89e2b461127922c3e4d7f42d7401 | |
| ToppCell | Striatum-Macroglia-OLIGODENDROCYTE|Striatum / BrainAtlas - Mouse McCarroll V32 | 9.53e-04 | 89 | 23 | 2 | ee1dd3571f5914a8274b71f9ca8b36132ae87fe1 | |
| ToppCell | Globus_pallidus-Macroglia-OLIGODENDROCYTE-O1-Trf-Oligodendrocyte.Trf.Mbp_(Mbp)-|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 1.11e-03 | 96 | 23 | 2 | 9673d03916705c675686bb4282dedd3dc5e98625 | |
| ToppCell | Globus_pallidus-Macroglia-OLIGODENDROCYTE-O1-Trf-Oligodendrocyte.Trf.Mbp_(Mbp)|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 1.11e-03 | 96 | 23 | 2 | 7e2810f5f5a17fcc7ae40edfd3e885740b575e29 | |
| ToppCell | Control-CD8+_T|Control / Disease group and Cell class | 1.11e-03 | 96 | 23 | 2 | 14e53fd2df39ac9d0b9cdc8b7ca2e95e53ac8bfe | |
| ToppCell | 343B-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-1|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 1.27e-03 | 103 | 23 | 2 | e28236a064a7c86e99e7e2edb1eb777f6034a9b4 | |
| ToppCell | TCGA-Testes-Primary_Tumor-Testicular_Germ_Cell_Tumor-Testicular_Germ_Cell_Tumor-2|TCGA-Testes / Sample_Type by Project: Shred V9 | 1.48e-03 | 111 | 23 | 2 | dbd6a30298c9f3b09b2b5ad93a14305e3438793d | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-iNKT/MAIT-T-cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.58e-03 | 115 | 23 | 2 | 3ab39d28717ae585d84c0e0686508faab2fc2e3b | |
| ToppCell | TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Ductal_and_Metaplastic_Carcinoma|TCGA-Breast / Sample_Type by Project: Shred V9 | 1.81e-03 | 123 | 23 | 2 | 51e49a64fbbf77e2ee21f45fd515d43282b11516 | |
| ToppCell | TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Ductal_and_Metaplastic_Carcinoma-4|TCGA-Breast / Sample_Type by Project: Shred V9 | 1.81e-03 | 123 | 23 | 2 | 11802979943a9205f10facda322fc220d4bf7133 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_ascending_limb_epithelial_cell-Ascending_Thin_Limb_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.08e-03 | 132 | 23 | 2 | 97e7d5f7086c6213aec4eaa581bc182338189029 | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT-T_cells-iNKT-MAIT|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.14e-03 | 134 | 23 | 2 | 92981dc68c1b3cdc53f9cf83386c47f0c6c98ae7 | |
| ToppCell | healthy_donor-Lymphocytic-T_cell-CD4+_T_cell_(ISG_high)|healthy_donor / Disease condition, Lineage, Cell class and subclass | 2.27e-03 | 138 | 23 | 2 | 97f5dc17522462133e582b508ad0ef036e656872 | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-T_cells-iNKT-MAIT|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.33e-03 | 140 | 23 | 2 | a8f3b01d03ee0bf0e752327a98d6b9035930c2b0 | |
| Drug | Aminocaproic Acid | 2.93e-06 | 3 | 23 | 2 | DB00513 | |
| Drug | 2-cyanoacetamide | 1.97e-05 | 162 | 23 | 4 | CID000007898 | |
| Drug | 2'-dC | 2.43e-05 | 171 | 23 | 4 | CID000000637 | |
| Drug | C0761 | 2.72e-05 | 8 | 23 | 2 | CID006321196 | |
| Drug | N-cyclopropylammelide | 2.72e-05 | 8 | 23 | 2 | CID000592814 | |
| Drug | 2-propylpentanoic acid; Down 200; 500uM; MCF7; HG-U133A | 4.32e-05 | 198 | 23 | 4 | 347_DN | |
| Drug | PAMBA | 7.56e-05 | 13 | 23 | 2 | CID000065526 | |
| Drug | 8a-c | 7.56e-05 | 13 | 23 | 2 | CID000066085 | |
| Drug | mafenide acetate | 7.56e-05 | 13 | 23 | 2 | CID000003998 | |
| Drug | uracil-4-acetic acid | 1.10e-04 | 93 | 23 | 3 | CID000073271 | |
| Drug | virus Tat | 1.32e-04 | 17 | 23 | 2 | CID000071655 | |
| Drug | 0 v 5 | 1.32e-04 | 17 | 23 | 2 | CID000444348 | |
| Disease | plasma plasminogen measurement | 4.82e-06 | 5 | 21 | 2 | EFO_0006309 | |
| Disease | chronic kidney disease, APOL1 risk genotype carrier status | 4.82e-06 | 5 | 21 | 2 | EFO_0003884, EFO_0009324 | |
| Disease | phosphoglycerides measurement | 5.26e-06 | 48 | 21 | 3 | EFO_0022291 | |
| Disease | total phospholipids in lipoprotein particles measurement | 7.11e-06 | 53 | 21 | 3 | EFO_0022315 | |
| Disease | triglycerides in HDL measurement | 7.11e-06 | 53 | 21 | 3 | EFO_0022317 | |
| Disease | angiostatin measurement | 7.22e-06 | 6 | 21 | 2 | EFO_0008024 | |
| Disease | cholesterol to total lipids in large LDL percentage | 8.40e-06 | 56 | 21 | 3 | EFO_0022235 | |
| Disease | triglycerides in LDL measurement | 8.40e-06 | 56 | 21 | 3 | EFO_0022320 | |
| Disease | low density lipoprotein particle size measurement | 9.35e-06 | 58 | 21 | 3 | EFO_0008593 | |
| Disease | lipoprotein A measurement, apolipoprotein A 1 measurement | 1.01e-05 | 7 | 21 | 2 | EFO_0004614, EFO_0006925 | |
| Disease | free cholesterol to total lipids in medium HDL percentage | 1.04e-05 | 60 | 21 | 3 | EFO_0022282 | |
| Disease | free cholesterol in HDL measurement | 1.09e-05 | 61 | 21 | 3 | EFO_0022264 | |
| Disease | triglycerides in medium LDL measurement | 1.14e-05 | 62 | 21 | 3 | EFO_0022322 | |
| Disease | triglycerides in small LDL measurement | 1.32e-05 | 65 | 21 | 3 | EFO_0022323 | |
| Disease | total lipids in very large HDL measurement | 1.38e-05 | 66 | 21 | 3 | EFO_0022312 | |
| Disease | cholesterol in very large HDL measurement | 1.58e-05 | 69 | 21 | 3 | EFO_0022229 | |
| Disease | phospholipids in large HDL measurement | 1.87e-05 | 73 | 21 | 3 | EFO_0022190 | |
| Disease | total lipids in large HDL | 1.95e-05 | 74 | 21 | 3 | EFO_0022189 | |
| Disease | free cholesterol in large HDL measurement | 2.37e-05 | 79 | 21 | 3 | EFO_0022157 | |
| Disease | cholesterol in large HDL measurement | 2.46e-05 | 80 | 21 | 3 | EFO_0021900 | |
| Disease | low density lipoprotein cholesterol measurement, alcohol consumption measurement | 4.66e-05 | 99 | 21 | 3 | EFO_0004611, EFO_0007878 | |
| Disease | triglyceride measurement, alcohol drinking | 4.66e-05 | 99 | 21 | 3 | EFO_0004329, EFO_0004530 | |
| Disease | total cholesterol measurement, intermediate density lipoprotein measurement | 4.66e-05 | 99 | 21 | 3 | EFO_0004574, EFO_0008595 | |
| Disease | triglyceride measurement, alcohol consumption measurement | 4.95e-05 | 101 | 21 | 3 | EFO_0004530, EFO_0007878 | |
| Disease | low density lipoprotein cholesterol measurement, alcohol drinking | 5.10e-05 | 102 | 21 | 3 | EFO_0004329, EFO_0004611 | |
| Disease | free cholesterol measurement, intermediate density lipoprotein measurement | 5.40e-05 | 104 | 21 | 3 | EFO_0008591, EFO_0008595 | |
| Disease | glycoprotein measurement | 8.07e-05 | 119 | 21 | 3 | EFO_0004555 | |
| Disease | Venous Thrombosis | 1.00e-04 | 21 | 21 | 2 | C0042487 | |
| Disease | Deep Vein Thrombosis | 1.00e-04 | 21 | 21 | 2 | C0149871 | |
| Disease | polyunsaturated fatty acid measurement | 1.07e-04 | 131 | 21 | 3 | EFO_0010733 | |
| Disease | free cholesterol measurement, low density lipoprotein cholesterol measurement | 1.22e-04 | 137 | 21 | 3 | EFO_0004611, EFO_0008591 | |
| Disease | cholesterol:total lipids ratio, low density lipoprotein cholesterol measurement | 1.42e-04 | 144 | 21 | 3 | EFO_0004611, EFO_0020943 | |
| Disease | low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 1.70e-04 | 153 | 21 | 3 | EFO_0004611, EFO_0020946 | |
| Disease | low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 1.70e-04 | 153 | 21 | 3 | EFO_0004611, EFO_0020944 | |
| Disease | alcohol consumption measurement, high density lipoprotein cholesterol measurement | 2.01e-04 | 162 | 21 | 3 | EFO_0004612, EFO_0007878 | |
| Disease | triglyceride measurement, low density lipoprotein cholesterol measurement | 2.16e-04 | 166 | 21 | 3 | EFO_0004530, EFO_0004611 | |
| Disease | cholesteryl esters to total lipids in large LDL percentage | 2.22e-04 | 31 | 21 | 2 | EFO_0022249 | |
| Disease | alcohol drinking, high density lipoprotein cholesterol measurement | 2.24e-04 | 168 | 21 | 3 | EFO_0004329, EFO_0004612 | |
| Disease | high density lipoprotein particle size measurement | 2.32e-04 | 170 | 21 | 3 | EFO_0008592 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 2.67e-04 | 34 | 21 | 2 | EFO_0008317, EFO_0008596, EFO_0020944 | |
| Disease | chylomicron measurement, triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement | 2.67e-04 | 34 | 21 | 2 | EFO_0008317, EFO_0008596, EFO_0020947 | |
| Disease | COVID-19 symptoms measurement | 2.83e-04 | 35 | 21 | 2 | EFO_0600019 | |
| Disease | linoleic acid measurement | 3.01e-04 | 186 | 21 | 3 | EFO_0006807 | |
| Disease | cholesteryl esters to total lipids in medium LDL percentage | 3.16e-04 | 37 | 21 | 2 | EFO_0022252 | |
| Disease | Hypercholesterolemia | 3.52e-04 | 39 | 21 | 2 | C0020443 | |
| Disease | omega-6 polyunsaturated fatty acid measurement | 3.57e-04 | 197 | 21 | 3 | EFO_0005680 | |
| Disease | lipoprotein-associated phospholipase A(2) measurement | 3.70e-04 | 40 | 21 | 2 | EFO_0004746 | |
| Disease | metabolic syndrome | 3.73e-04 | 200 | 21 | 3 | EFO_0000195 | |
| Disease | cholesteryl esters to total lipids in small LDL percentage | 4.08e-04 | 42 | 21 | 2 | EFO_0022255 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 4.08e-04 | 42 | 21 | 2 | EFO_0008317, EFO_0008596, EFO_0020945 | |
| Disease | free cholesterol to total lipids in very small VLDL percentage | 4.28e-04 | 43 | 21 | 2 | EFO_0022290 | |
| Disease | saturated fatty acids measurement | 4.69e-04 | 45 | 21 | 2 | EFO_0022304 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio | 4.90e-04 | 46 | 21 | 2 | EFO_0008317, EFO_0008596, EFO_0020943 | |
| Disease | triglyceride measurement, very low density lipoprotein cholesterol measurement | 5.19e-04 | 224 | 21 | 3 | EFO_0004530, EFO_0008317 | |
| Disease | triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement | 5.26e-04 | 225 | 21 | 3 | EFO_0008317, EFO_0020947 | |
| Disease | total lipids in lipoprotein particles measurement | 5.34e-04 | 48 | 21 | 2 | EFO_0022309 | |
| Disease | phospholipids:total lipids ratio | 5.39e-04 | 227 | 21 | 3 | EFO_0020946 | |
| Disease | polyunsaturated fatty acids to total fatty acids percentage | 5.79e-04 | 50 | 21 | 2 | EFO_0022303 | |
| Disease | cholesterol to total lipids in small HDL percentage | 6.02e-04 | 51 | 21 | 2 | EFO_0022240 | |
| Disease | free cholesterol to total lipids in small HDL percentage | 6.02e-04 | 51 | 21 | 2 | EFO_0022285 | |
| Disease | polyunsaturated fatty acids to monounsaturated fatty acids ratio | 6.02e-04 | 51 | 21 | 2 | EFO_0022302 | |
| Disease | monokine induced by gamma interferon measurement | 6.26e-04 | 52 | 21 | 2 | EFO_0008236 | |
| Disease | very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 6.27e-04 | 239 | 21 | 3 | EFO_0008317, EFO_0020945 | |
| Disease | free cholesterol to total lipids in small LDL percentage | 6.50e-04 | 53 | 21 | 2 | EFO_0022286 | |
| Disease | cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement | 6.57e-04 | 243 | 21 | 3 | EFO_0004612, EFO_0020944 | |
| Disease | triglycerides in medium HDL measurement | 6.75e-04 | 54 | 21 | 2 | EFO_0022321 | |
| Disease | triglycerides in very large HDL measurement | 7.00e-04 | 55 | 21 | 2 | EFO_0022324 | |
| Disease | Antithrombotic agent use measurement | 7.00e-04 | 55 | 21 | 2 | EFO_0009925 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| YAWFSSHTSPLYWDC | 231 | P54793 | |
| YEVTWYISWSPCTKC | 86 | Q9HC16 | |
| VTCYLTWSPCSSCAW | 76 | Q6NTF7 | |
| WYFPCTKSYWFGEES | 856 | O95477 | |
| YQVTWYTSWSPCPDC | 86 | Q9NRW3 | |
| YRVTWFTSWSPCYDC | 76 | Q9GZX7 | |
| PTQLWEECSSWYYYV | 316 | Q8N6M6 | |
| ACDSYWTSVHPEYWT | 51 | Q9UKW6 | |
| YFWQYGHWTECSVTC | 826 | P58397 | |
| CEPQCAWSEWLDYSY | 2871 | Q9HC84 | |
| CEPQCAWSEWLDYSY | 3571 | Q9HC84 | |
| WCVLSGNCISYWTYP | 1006 | Q9NQW6 | |
| LRWFYSASDYISDCW | 511 | Q9Y2G8 | |
| LPTCWDYWTYAGSLT | 221 | P35218 | |
| WCYTTDPCVRWEYCN | 1561 | P08519 | |
| RPYSCNWESCSWSFF | 311 | Q5JT82 | |
| LWTNLTVYWKSECCY | 91 | Q68CP4 | |
| YACYCPWCYERSWFS | 31 | Q3MIV0 | |
| MCCLRYWYTPESWIC | 46 | Q96EK7 | |
| SWFTWYCCTRTLTNT | 181 | Q92521 | |
| SSPWCDYASYWTSSP | 376 | Q93075 | |
| WCFTTDPSVRWEYCN | 436 | P00747 | |
| CWCWDLEYGYPSYTE | 556 | Q8TDI8 | |
| WYNTWRMEPYNSSCC | 106 | Q8NCR6 | |
| RWEYSYSSWTLFTCE | 531 | Q5SRE5 |